Company Introduction

BIOS is established in 2024 and registered in Hong Kong, China. We focuses on the product development and commercial production of hemoglobin oxygen carrier-related medicinal product and medical devices. In early 2024, BIOS has completed the acquisition of New Alpha Innovation (NAI) Limited’s hemoglobin-based oxygen carrier (HBOC) project and Redpharm Biotechnology Limited, including all registered and registering drug certificates, intellectual property rights, and proprietary technologies around the world; such that BIOS has become the global leading company in artificial hemoglobin area.

Products effectively provide oxygen to the whole body and various tissues and organs through intravenous injection and extracorporeal circulation. The company has six core products: Oxapex®, Oxamex®, YQ23®, OP-101, HB-201, and AP-301 for human and animal use respectively.

In 2012, Oxapex® was certificated as a new drug in New Zealand. It is a kind of animal hemoglobin treatment drug. After injection, Oxapex® can increase the hemoglobin content in the blood, improve the body's oxygen load, improve tissue oxygenation, and effectively reduce the clinical symptoms of acute anemia. After that, it obtained Minor Use permits from the APVMA and the US FDA respectively, and included in the Index of Legally Marketed new drugs for the treatment of a small number of animal species Unapproved New Animal Drugs for Minor Species.

In 2023, Oxamex® was approved by the CVMP, which is part of the EMA, for the treatment of dogs with hemorrhagic shock.

In 2023, Oxamex® was approved by the British VMD for the treatment of dogs in hemorrhagic shock.

In 2020, YQ23® completed Phase I clinical trials in humans in the UK.

In 2020, YQ23® began Phase Ib clinical trials in Hong Kong, China for Advanced Solid Tumors.

In 2021, YQ23® carried out Phase Ib/IIa clinical trials in Hong Kong, China for Critical Limb Ischemia (CLI).

Since 2020, HB-201 and AP-301 have respectively conducted a number of preclinical studies on animal anemia, hemorrhagic shock, pulmonary fibrosis, tumor sensitization, cardiovascular and cerebrovascular diseases caused by various diseases.

Team

Mr. Cheng Chi-Heng

Chairman

• Vice-chairman and executive director of Chow Tai Fook Jewellery Group Limited;

• Founder of Cyber-Medic, a popular medical professional website;

• Non-executive Director of New World Development Company Limited.


Wong BingLou

CSO

• Consultant and visiting professor of Chengdu Institute of Blood Transfusion, Chinese Academy of Medical Sciences;

• Editor of the first and second editions of Chinese Blood Transfusion;

• Visiting Professor, School of Life Sciences, Chinese University of Hong Kong;

• Founder and Chairman of BING Biotech Limited;

• Head of R&D Department of Taron Solutions Limited;

• Director of Hong Kong Aihua Biomedicine Limited;

• Former Scientific Director of New Beta Innovation Limited (YQ23);

• Former founder, Vice President and Chief Technology Officer of Biopure Corporation (HBOC-201);

• 50 years of experience in developing biologics;

• Experts in enzyme technology, biologics, biological processes, fermentation, protein purification and protein engineering;

• He owns a series of patents and has licensed them to many of the world's leading companies such as Roche and Teva;

• Successfully developed and commercialized hemoglobin oxygen-carrying protein products (YQ23 and HBOC-201).

Partner Units

  • The Second Affiliated Hospital of Nanjing Medical University

  • Institute of Blood Transfusion, Chinese Academy of Medical Sciences

  • Sun Yat-sen University Cancer Center

  • Sun Yat-sen Memorial Hospital

  • Sichuan Provincial People's Hospital

  • The First Hospital of Lanzhou University

  • The First Affiliated Hospital Of Xi’an Jiaotong University

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University

  • Fuwai Hospital Chinese Academy of Medical Sciences

  • The First Hospital of Jilin University

  • Institute of Radiology, Chinese Academy of Medical Sciences

  • Shandong First Medical University

Vision/Mission

Vision

Oxygen drives life

Mission

Save a life and change their world; Saving countless lives and changing the whole world.

Select Language and Region

Contact Us

©2024 BIOS Biotechnology Co., Ltd All Rights Reserved.

Company Introduction

BIOS is established in 2024 and registered in Hong Kong, China. We focuses on the product development and commercial production of hemoglobin oxygen carrier-related medicinal product and medical devices. In early 2024, BIOS has completed the acquisition of New Alpha Innovation (NAI) Limited’s hemoglobin-based oxygen carrier (HBOC) project and Redpharm Biotechnology Limited, including all registered and registering drug certificates, intellectual property rights, and proprietary technologies around the world; such that BIOS has become the global leading company in artificial hemoglobin area.

Products effectively provide oxygen to the whole body and various tissues and organs through intravenous injection and extracorporeal circulation. The company has six core products: Oxapex®, Oxamex®, YQ23®, OP-101, HB-201, and AP-301 for human and animal use respectively.

In 2012, Oxapex® was certificated as a new drug in New Zealand. It is a kind of animal hemoglobin treatment drug. After injection, Oxapex® can increase the hemoglobin content in the blood, improve the body's oxygen load, improve tissue oxygenation, and effectively reduce the clinical symptoms of acute anemia. After that, it obtained Minor Use permits from the APVMA and the US FDA respectively, and included in the Index of Legally Marketed new drugs for the treatment of a small number of animal species Unapproved New Animal Drugs for Minor Species.

In 2023, Oxamex® was approved by the CVMP, which is part of the EMA, for the treatment of dogs with hemorrhagic shock.

In 2023, Oxamex® was approved by the British VMD for the treatment of dogs in hemorrhagic shock.

In 2020, YQ23® completed Phase I clinical trials in humans in the UK.

In 2020, YQ23® began Phase Ib clinical trials in Hong Kong, China for Advanced Solid Tumors.

In 2021, YQ23® carried out Phase Ib/IIa clinical trials in Hong Kong, China for Critical Limb Ischemia (CLI).

Since 2020, HB-201 and AP-301 have respectively conducted a number of preclinical studies on animal anemia, hemorrhagic shock, pulmonary fibrosis, tumor sensitization, cardiovascular and cerebrovascular diseases caused by various diseases.

Team

  • Mr. Cheng Chi-Heng

    Chairman

    • Vice-chairman and executive director of Chow Tai Fook Jewellery Group Limited;

    • Founder of Cyber-Medic, a popular medical professional website;

    • Non-executive Director of New World Development Company Limited.


  • Wong BingLou

    CSO

    • Consultant and visiting professor of Chengdu Institute of Blood Transfusion, Chinese Academy of Medical Sciences;

    • Editor of the first and second editions of Chinese Blood Transfusion;

    • Visiting Professor, School of Life Sciences, Chinese University of Hong Kong;

    • Founder and Chairman of BING Biotech Limited;

    • Head of R&D Department of Taron Solutions Limited;

    • Director of Hong Kong Aihua Biomedicine Limited;

    • Former Scientific Director of New Beta Innovation Limited (YQ23);

    • Former founder, Vice President and Chief Technology Officer of Biopure Corporation (HBOC-201);

    • 50 years of experience in developing biologics;

    • Experts in enzyme technology, biologics, biological processes, fermentation, protein purification and protein engineering;

    • He owns a series of patents and has licensed them to many of the world's leading companies such as Roche and Teva;

    • Successfully developed and commercialized hemoglobin oxygen-carrying protein products (YQ23 and HBOC-201).

Partner Units
The Second Affiliated Hospital of Nanjing Medical University
Institute of Blood Transfusion, Chinese Academy of Medical Sciences
Sun Yat-sen University Cancer Center
Sun Yat-sen Memorial Hospital
Sichuan Provincial People's Hospital
The First Hospital of Lanzhou University
The First Affiliated Hospital Of Xi’an Jiaotong University
Ruijin Hospital Affiliated to Shanghai Jiao Tong University
Fuwai Hospital Chinese Academy of Medical Sciences
The First Hospital of Jilin University
Institute of Radiology, Chinese Academy of Medical Sciences
Shandong First Medical University
Vision/Mission
  • Vision
    Oxygen drives life
  • Mission
    Save a life and change their world; Saving countless lives and changing the whole world.

©2024 BIOS Biotechnology Co., Ltd All Rights Reserved.

x